MongoDB Stock Sinks 14% as Atlas Growth Misses Expectations 
Honda Targets $9.4 Billion in Cost Cuts as China EV Competition Intensifies 
Microsoft to Reveal Azure Revenue in Major Reporting Shake-Up 
US Tech Giants’ AI Bond Boom Raises Euro Zone Borrowing Risks 
Volkswagen Approves 50,000 More Job Cuts in Major Restructuring 
South Korea, US Discuss Chip Investments Amid Tariff Plans 
Fast Retailing Shares Drop as Uniqlo Japan August Sales Fall 
Adobe Names Anil Chakravarthy CEO as AI Push Accelerates 
BP Names Ian Tyler Permanent Chairman After Governance Shake-Up 
OpenAI Launches GPT-6 Astra With Advanced AI Agent Capabilities 
CATL Shares Fall as Hungary Plant Faces Safety Halt 
ByteDance Secures $29.6 Billion Loan to Boost AI Investment 
Nvidia Eyes $2.5 Billion Investment in Thinking Machines Lab 
Berkshire Hathaway Eyes Bigger Stakes in Japan’s Top Trading Houses 
Tesla Cybercab Launch Puts Robotaxi Ambitions in Focus 
Thomson Reuters C-Track Cyberattack Hits Courts Across U.S. and Canada 
Milei Threatens Falkland Oil Firms With Sanctions 
Add as a preferred source on Google
PLEASANTON, Calif. , Feb. 22, 2018 --
Natus Medical Incorporated (NASDAQ:BABY) announced that its Board of Directors has authorized the repurchase of up to $30 million of the Company's common stock. The expiration date is set for February 26, 2019.
The Company intends to use cash on hand, cash generated from operations, existing credit facilities or other financing to fund the share repurchase program. As of December 31, 2017, the Company had cash and cash equivalents of approximately $89 million and availability under an existing line of credit of $70 million.
The timing and amount of repurchases will be subject to applicable legal requirements including federal and state securities laws. Purchases will be made in open market transactions effected through a broker-dealer at prevailing market prices, in block trades, or in privately negotiated transactions. Shares may also be purchased pursuant to a trading plan meeting the requirements of Rule 10b5-1 under the Securities Exchange Act of 1934, as amended, which would permit shares to be repurchased when the Company might otherwise be precluded from doing so under insider trading laws.
About Natus Medical Incorporated
Natus is a leading provider of healthcare products and services used for the screening, detection, treatment, monitoring and tracking of common medical ailments in newborn care, hearing impairment, neurological dysfunction, neurosurgery, epilepsy, sleep disorders, and balance and mobility disorders.
Additional information about Natus Medical can be found at www.natus.com.
Natus Medical Incorporated
Jonathan A. Kennedy
Executive Vice President and Chief Financial Officer
(925) 223-6700
[email protected]
